Based on an overall attractive drug-like profile, RMC-6236 was advanced into clinical development and is undergoing evaluation in a phase I/Ib trial as a monotherapy in patients with previously treated, advanced solid tumors, including NSCLC, and PDAC, with KRAS glycine 12 mutant (KRASG12X) genotypes (NCT05379985). Here, KRAS is linked to non-small cell lung carcinoma.